Research Atlas · source screening

Plitidepsin

An attributable first-pass index of PubMed records whose titles name this governed identity. Records are sorted by publication date, not by evidence strength. Inclusion does not establish efficacy, safety, or a clinical indication.

Title-search results

65

Shown with stable PMIDs

25

Search recorded

2026-09-26

Source: NCBI PubMed / MEDLINE · exact query: "Plitidepsin"[Title] · up to 25 recent title matches per identity. Each result links to its PubMed record.

1. Plitidepsin induces apoptosis in glioma cells through β-TrCP-mediated ubiquitination and degradation of BMI1.

   Naunyn Schmiedebergs Arch Pharmacol · 2026 Jul 11 · PMID 42432349 · DOI 10.1007/s00210-026-05507-2

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

2. Plitidepsin in combination with dexamethasone (ADMYRE trial) versus an external control arm of pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.

   Ann Hematol · 2026 Jan 17 · PMID 41545603 · DOI 10.1007/s00277-026-06811-w

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

3. Can plitidepsin be used as an antiviral against RSV?

   mSphere · 2025 Dec 23 · PMID 41277830 · DOI 10.1128/msphere.00127-25

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

4. Pharmacological reprogramming of plitidepsin as a SARS-CoV-2 inhibitor.

   Mol Aspects Med · 2025 Dec · PMID 41218566 · DOI 10.1016/j.mam.2025.101412

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

5. Randomized Phase III Study (ADMYRE) of Plitidepsin in Combination with Dexamethasone vs. Dexamethasone Alone in Relapsed/Refractory Multiple Myeloma: Results for Patients Aged <75 Years.

   Cancers (Basel) · 2025 Oct 29 · PMID 41228275 · DOI 10.3390/cancers17213482

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

6. Functional characteristics of plitidepsin as an antiviral treatment against monkeypox virus infection.

   Antiviral Res · 2025 Sep · PMID 40675496 · DOI 10.1016/j.antiviral.2025.106238

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

7. A Phase III Randomized Controlled Trial of Plitidepsin, a Marine-Derived Compound, in Hospitalized Adults With Moderate COVID-19.

   Clin Infect Dis · 2024 Oct 15 · PMID 39182994 · DOI 10.1093/cid/ciae227

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

8. Outcomes and clinical characteristics of the compassionate use of plitidepsin in COVID-19 patients with solid tumours, haematological malignancies or anti-CD20 antibody treatment.

   Infect Dis (Lond) · 2024 Jul · PMID 38743059 · DOI 10.1080/23744235.2024.2351043

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

9. Plitidepsin as an Immunomodulator against Respiratory Viral Infections.

   J Immunol · 2024 Apr 15 · PMID 38416036 · DOI 10.4049/jimmunol.2300426

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

10. Outcomes and clinical characteristics of the compassionate use of plitidepsin for immunocompromised adult patients with COVID-19.

    Int J Infect Dis · 2023 Oct · PMID 37481109 · DOI 10.1016/j.ijid.2023.07.011

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

11. Plitidepsin in adult patients with COVID-19 requiring hospital admission: A long-term follow-up analysis.

    Front Cell Infect Microbiol · 2023 · PMID 36909731 · DOI 10.3389/fcimb.2023.1097809

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

12. Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma.

    Cancer Med · 2023 Feb · PMID 36127823 · DOI 10.1002/cam4.5250

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

13. Unraveling the antiviral activity of plitidepsin against SARS-CoV-2 by subcellular and morphological analysis.

    Antiviral Res · 2022 Apr · PMID 35231500 · DOI 10.1016/j.antiviral.2022.105270

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

14. Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19.

    Life Sci Alliance · 2022 Apr · PMID 35012962 · DOI 10.26508/lsa.202101200

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

15. Computational Prediction of the Potential Target of SARS-CoV-2 Inhibitor Plitidepsin via Molecular Docking, Dynamic Simulations and MM-PBSA Calculations.

    Chem Biodivers · 2022 Feb · PMID 34813168 · DOI 10.1002/cbdv.202100719

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

16. Hunting the main protease of SARS-CoV-2 by plitidepsin: Molecular docking and temperature-dependent molecular dynamics simulations.

    Amino Acids · 2022 Feb · PMID 34807314 · DOI 10.1007/s00726-021-03098-1

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

17. Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leukemia.

    J Hematol Oncol · 2022 Jan 10 · PMID 35012608 · DOI 10.1186/s13045-021-01220-0

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

18. Plitidepsin for the management of a cancer patient infected with SARS-CoV-2 while receiving chemotherapy.

    Ann Oncol · 2021 Oct · PMID 34242743 · DOI 10.1016/j.annonc.2021.07.003

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

19. [Plitidepsin, an inhibitor of the cell elongation factor eEF1a, and molnupiravir an analogue of the ribonucleoside cytidine, two new chemical compounds with intense activity against SARS-CoV-2].

    Rev Esp Quimioter · 2021 Oct · PMID 33902254 · DOI 10.37201/req/042.2021

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

20. Preclinical Activity of Plitidepsin Against Clear Cell Carcinoma of the Ovary.

    Anticancer Res · 2021 Sep · PMID 34475047 · DOI 10.21873/anticanres.15232

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

21. Plitidepsin: Mechanisms and Clinical Profile of a Promising Antiviral Agent against COVID-19.

    J Pers Med · 2021 Jul 16 · PMID 34357135 · DOI 10.3390/jpm11070668

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

22. Plitidepsin has a positive therapeutic index in adult patients with COVID-19 requiring hospitalization.

    medRxiv · 2021 May 25 · PMID 34075384 · DOI 10.1101/2021.05.25.21257505

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

23. Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.

    Front Pharmacol · 2021 · PMID 33841165 · DOI 10.3389/fphar.2021.646676

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

24. Plitidepsin: a Repurposed Drug for the Treatment of COVID-19.

    Antimicrob Agents Chemother · 2021 Mar 18 · PMID 33558296 · DOI 10.1128/AAC.00200-21

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

25. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.

    Science · 2021 Feb 26 · PMID 33495306 · DOI 10.1126/science.abf4058

    Source metadata only · evidence grade unassigned · scientific conclusions pending review